- SynGenSys, a synthetic biology company spun out of the University of Sheffield, appoints Dr. Andy Racher as Commercial Operations Director
- Dr. Racher brings over 30 years of experience in biotechnology to lead commercialisation efforts
- The company secured £1.8m in seed funding in Autumn 2023 to expand its product offerings
SynGenSys, a fast-growing biotechnology company spun out of the University of Sheffield, has announced the appointment of Dr. Andy Racher as its Commercial Operations Director.
SynGenSys is a leader in the field of synthetic biology, specialising in the design and construction of synthetic genetic components. This innovative approach unlocks the potential for next-generation biomedicines and biomanufacturing processes. The company's core technology platform utilises bioinformatic analysis of large-scale biological data to engineer novel synthetic genetic parts tailored to specific products or processes.
Dr Racher’s appointment follows a successful angel-led £1.8m seed fundraise, secured in Autumn 2023, which was facilitated by legal counsel Freeths and corporate finance advisors Translink. This vital funding will propel SynGenSys' commercialisation efforts, enabling the company to expand its product offerings and services to customers worldwide.
SynGenSys welcomes Dr Andy Racher to its leadership team as Commercial Operations Director. Dr Racher brings over three decades of experience in the biotechnology sector, having held numerous senior positions at Lonza Biologics, a leading Contract Development and Manufacturing Organization (CDMO). His extensive experience in R&D IP Strategy, Future Technologies, Process Development Sciences, Cell Culture Process Development, and Cell Culture science positions him perfectly to spearhead SynGenSys' commercial operations.
“I am delighted to be joining the SynGenSys team at such a pivotal time in the company's development,” said Dr Racher. “I am eager to leverage my experience to build a robust commercial function and propel SynGenSys' market reach.”
Professor David James, co-founder and Chief Technology Officer of SynGenSys, commented, “We are thrilled to welcome Dr. Racher to our team. His appointment marks the first of several strategic hires planned as we prepare to offer our unique product portfolio and services to a global customer base.” Professor James continued, “This seed funding round and Dr. Racher’s appointment position SynGenSys for significant growth and impact in the field of synthetic biology.”
SynGenSys is dedicated to pioneering synthetic biology solutions for next-generation biomedicines and biomanufacturing processes. The company's expertise lies in designing and constructing synthetic genetic components tailored to specific applications. SynGenSys' vision is to revolutionise the development and manufacturing of biopharmaceuticals and gene therapies through its innovative synthetic biology platform.